Literature DB >> 15303575

Breast cancer stage at time of detection in women with systemic lupus erythematosus.

S Bernatsky1, A Clarke, R Ramsey-Goldman, J-F Boivin, L Joseph, Raghu Rajan, S Manzi.   

Abstract

Mounting evidence suggests an increased cancer risk in several autoimmune diseases, including systemic lupus erythematosus (SLE). However, greater scrutiny for cancer in subjects with chronic disease (compared to the general population) might explain this apparent association. If so, one would expect cancers in SLE to be diagnosed at earlier stages than in the general population. This might be particularly evident in cancers where screening is available, such as breast cancer. We linked the University of Pittsburgh lupus cohort with the Pennsylvania Cancer Registry to determine the frequency distribution for stage at diagnosis of invasive breast cancers in the SLE subjects. Data on staging of cancers occurring in the general population of Pennsylvania were obtained from The US Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. A lower percentage of women with SLE presented with localized breast cancer (nine of the 16, 56.2%) compared to the general population of women (63.5%). Although not definitive, this evidence suggests that cancers in SLE are not necessarily diagnosed at earlier stages than in the general population.

Entities:  

Mesh:

Year:  2004        PMID: 15303575     DOI: 10.1191/0961203304lu1008xx

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

2.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

3.  No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.

Authors:  Zahra Rezaieyazdi; Samira Tabaei; Yalda Ravanshad; Javad Akhtari; Hassan Mehrad-Majd
Journal:  Clin Rheumatol       Date:  2018-01-02       Impact factor: 2.980

4.  Malignancy in systemic lupus erythematosus: what have we learned?

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.